CLINICAL AND EXPERIMENTAL STUDY OF BESTATIN FOR ESOPHAGEAL CANCER
1981; Elsevier BV; Linguagem: Inglês
10.1016/b978-0-08-027993-0.50018-7
AutoresKaichi Isono, Shoichi Onoda, Tatsuo Ishikawa, Yoshio Koide, Hiroshi Satō,
Tópico(s)Synthesis and Biological Evaluation
ResumoThis chapter describes a clinical and experimental study of bestatin for esophageal cancer. The schedule of preoperative combined therapy for patients with esophageal cancer in department is shown. It was found that although irradiation and bleomycin were principally administered at the end of routine examination upon admission, the immunotherapeutic agent was given at the moment of admission and the dose of bestatin was 30 mg/day from admission to the day before surgery. The effectiveness was evaluated clinically according to radiographic features observed 7–10 days after the end of preoperative combined therapy in comparison with those observed upon admission. The total dose of bleomycin was 100 mg and that of bestatin was approximately 1000 mg though it was influenced by the duration from admission to surgery. After such preoperative treatment, the surgically resected specimens were investigated histopathologically for therapeutic effects and all revealed an effectiveness of Ef2, 3. It was found that the effective rate was 100% and more than 2/3 of cancer cells went into degeneration and necrosis.
Referência(s)